MedPacto is an innovative drug discovery and development company based in South Korea that delivers therapeutics targeting cancer and autoimmune diseases. Our expertise lies in utilizing genome-based methods to identify novel targets and to develop first-in-class and best-in-class drugs.
In 2013, MedPacto spun out from Theragen Etex (KOSDAQ, KRX, 066700), a global leader in genomics. Our forefront asset, Vactosertib (TEW-7197, NOV-1301), is a potent, highly selective TGF-β type 1 receptor inhibitor, which is currently in pivotal trials in the US and Korea. Additionally, MedPacto has a portfolio of competitive compounds to address the unmet needs of our important customer, the patient.